Clinical Trial Results: GD2-SADA:177Lu-DOTA Complex in Patients With Solid Tumors Known to Express GD2 [Phase 1]

View source ↗

Summary

Phase 1 trial of GD2-SADA:177Lu-DOTA complex for GD2-expressing solid tumors was terminated; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• High-risk Neuroblastoma
• Malignant Melanoma
• Sarcoma
• Small Cell Lung Cancer

Drugs mentioned

• GD2-SADA:177Lu-DOTA Complex

Snippet

Sponsor: Y-mAbs Therapeutics | Conditions: SCLC, Malignant Melanoma | Phase 1 | Status: TERMINATED | Results posted: 2026-06-18